Humacyte, Inc. (HUMA) Submits Marketing Authorization Application in Israel for Symvess

Humacyte, Inc. (NASDAQ:HUMA) is one of the 11 Best High Volume Penny Stocks to Buy Now. On March 17, 2026, Humacyte, Inc. (NASDAQ:HUMA) submitted a Marketing Authorization Application to the Israel Ministry of Health for approval of its acellular tissue-engineered vessel, Symvess, for arterial trauma repair. The company is also pursuing a pathway to make Symvess available in Israel on a hospital-by-hospital basis ahead of potential approval. Symvess is currently approved by the FDA for extremity vascular trauma, while other uses remain investigational and not yet approved by regulatory agencies.

Last month, Humacyte, Inc. (NASDAQ:HUMA) presented long-term data on Symvess at the Vascular & Endovascular Surgery Society Annual Winter Meeting 2026. In the V005 trial, the product maintained structural integrity and showed low infection rates with high levels of limb salvage over follow-up periods of up to 36 months. Among 54 patients treated in the Phase 2/3 study where standard vein grafts were not feasible, outcomes stabilized after early complications, with infection-free rates reaching 92.9% from months 3 to 36 and no infections reported after day 37. Limb salvage rates were 87.3% at 12 months and 82.5% at 24 months.

Copyright: paylessimages / 123RF Stock Photo

Humacyte, Inc. (NASDAQ:HUMA) develops and manufactures bioengineered human tissues designed for implantation across multiple therapeutic areas.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.